Innoviva (INVA) Profit After Tax (2010 - 2026)
Innoviva's (INVA) quarterly Profit After Tax came in at $186.6 million in Q1 2026, up 500.56% YoY from $31.1 million in Q1 2025, and up 250.12% on a QoQ basis from -$124.3 million in Q4 2025.
Innoviva (INVA) Profit After Tax (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Profit After Tax data on file, last reported at $186.6 million in Q1 2026.
- Quarterly Profit After Tax rose 500.56% year-over-year to $186.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $233.0 million (up 403.36% YoY) and the FY2025 annual result came in at $271.2 million, up 1059.22% from the prior year.
- Profit After Tax advanced to $186.6 million in Q1 2026, from -$124.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $288.6 million in Q3 2022 to a low of -$124.3 million in Q4 2025.
- A 5-year average of $29.9 million and a median of $2.6 million in 2024 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 3397.12% in 2025, down 4880.69% in 2025.
- Tracing INVA's Profit After Tax over 5 years: stood at -$10.3 million in 2022, then tumbled by 92.43% to -$19.8 million in 2023, then jumped by 113.1% to $2.6 million in 2024, then plunged by 4880.69% to -$124.3 million in 2025, then surged by 250.12% to $186.6 million in 2026.
- The last three Profit After Tax figures came in at $186.6 million (Q1 2026), -$124.3 million (Q4 2025), and $107.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | -83.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -83.42 Mn |
| Mar 31, 2026 | 186.60 Mn |
| Dec 31, 2025 | -124.30 Mn |
| Sep 30, 2025 | 107.01 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.58 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | -35.88 Mn |
| Mar 31, 2024 | -44.87 Mn |
| Dec 31, 2023 | -19.85 Mn |
| Sep 30, 2023 | 118.19 Mn |
| Jun 30, 2023 | -28.35 Mn |
| Mar 31, 2023 | 34.87 Mn |
| Dec 31, 2022 | -10.31 Mn |
| Sep 30, 2022 | 288.58 Mn |
| Jun 30, 2022 | -24.04 Mn |
| Mar 31, 2022 | 37.86 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 323.19 Mn |